Checked 2026-11-10. Independent clinical review has not been completed. WADAFUK is independent of WADA and does not provide medical advice or an individual anti-doping determination.
Prohibited at all times
2026: prohibited at all times (S2). [1]
2026 List, S2.2.4, printed page 8 · 2026 rules apply from 1 January 2026. Any 2027 material below concerns future rules from 1 January 2027; it is not current clearance.
Identity and acute biological effects
GHRP-6 is a synthetic growth-hormone-releasing hexapeptide. A placebo-comparison study in healthy men reported acute changes in growth hormone, ACTH, cortisol and stage-2 sleep. These hormonal and sleep measurements are not evidence of improved sporting performance or recovery. [2]
- The available primary abstract was truncated. Full methods, the complete sample description and detailed safety outcomes were not independently readable.
Health risks and evidence gaps
FDA identifies limited clinical data, potential peptide-impurity or aggregation risks, and concerns about increased cortisol and blood glucose associated with reduced insulin sensitivity. These concerns do not quantify individual risk or establish a safe regimen. [3]
FDA’s CJC-1295 assessment also documents GHRP-6-containing blend marketing. A blend label is not an assay or evidence that findings from one ingredient apply to the entire product. [4]
What remains uncertain
- The 2026 COURAGE-2 stroke report could not be read sufficiently to verify its population, combination intervention and outcomes; those claims are withheld.
- No long-term athletic-benefit, current-product identity or ordinary-food exposure conclusion is offered.
Check the sources.
These are concise editorial paraphrases of selected sources, not a systematic review or a reproduction of source tables. Access depth is shown for each reference; an abstract-only check cannot resolve details found only in a full paper.
- WADA 2026 Prohibited List ↗Accessed 2026-11-10 · official_full_text_relevant_sections
Effective date; S0 printed page 4; S2 printed pages 7–8
- 1995 GHRP-6 study of sleep and hormonal responses ↗Accessed 2026-11-10 · abstract_only
PubMed abstract; DOI 10.1159/000126883
- FDA: bulk substances that may present significant compounding safety risks ↗Accessed 2026-11-10 · official_full_text_relevant_sections
GHRP-2 and GHRP-6 entries
- FDA staff review: CJC-1295 related substances, 2024 ↗Accessed 2026-11-10 · official_full_text_relevant_sections
Five related forms; pharmacology; human safety and marketing
Check the current official WADA List and the relevant anti-doping authority for your sport, product, route and circumstances. Do not stop or change necessary treatment based on this page. Ask a qualified clinician about health decisions. Missing evidence does not establish safety.